Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab
Khalid Jazieh(Mayo Clinic), Anant Madabhushi(Emory University), Mohamed M. Gad(Hospital of the University of Pennsylvania), Pradnya D. Patil(Cleveland Clinic), Mohammadhadi Khorrami(Case Western Reserve University), Prabhakar Rajiah(Southwestern Medical Center), Amit Gupta(University of Washington), Pingfu Fu(Medical College of Wisconsin), Michael Gilkey(Case Western Reserve University), Charles Nock(FrontLine Service), Nathan A. Pennell(Cleveland Clinic), Vidya Sankar Viswanathan(Case Western Reserve University), Anas M. Saad(The Barbara Ann Karmanos Cancer Institute)
Cited by 57
Related Papers
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Predicting cancer outcomes with radiomics and artificial intelligence in radiology
|Nature Reviews Clinical Oncology|2021|810
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2020|484